Log in to search using one of your social media accounts:

 

US Court of Appeals reverses District Court ’s ruling on Aloxi patent
A panel of the United States Court of Appeals for the Federal Circuit has reversed the opinion of the District Court for the District of New Jersey for Aloxi (palonosetron hydrochloride) injection. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

Mundipharma and Helsinn expand licensing and distribution agreements for Aloxi and Akynzeo
Mundipharma and Helsinn Group have expanded licensing and distribution agreements for anti-emetic prophylactic agents Aloxi and Akynzeo to cover additional markets such as the Middle East, Africa, Latin America and Indonesia. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 16, 2017 Category: Pharmaceuticals Source Type: news

Aloxi Capsules (Palonosetron HCl Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

‘ Botox Police ’ : FDA crime unit draws fire over import crackdown
(Reuters) – On April 5, 2012, a criminal investigator from the Food and Drug Administration named Robert West charged into an oncology clinic in Greenville, Tennessee. West was chasing a lead that Dr. Anindya Sen and his wife, the clinic’s office manager Patricia Posey Sen, purchased an unapproved Turkish version of the cancer drug Avastin. But “Cowboy Bob,” as some defense attorneys call him, did not realize his interview was caught on the clinic’s surveillance cameras. West told Posey Sen she was guilty of buying counterfeit drugs and looked like a “deer in the headlights,” court...
Source: Mass Device - September 9, 2016 Category: Medical Equipment Authors: MassDevice Tags: Cosmetic/Aesthetic Food & Drug Administration (FDA) Source Type: news

Helsinn and Eisai extend partnership for prevention of CINV
Helsinn and Eisai will continue to co-promote and distribute Aloxi (palonosetron HCl) injection for the prevention of chemotherapy-induced nausea and vomiting (CINV). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 22, 2016 Category: Pharmaceuticals Source Type: news

The European Commission Approves ALOXI(R) (palonosetron HCl) Injection to Prevent Nausea and Vomiting Due to Chemotherapy in Children as Young as One Month
The European approval of ALOXI® for paediatric use follows the FDA approval in May 2014 of ALOXI® for paediatric use in the US LUGANO, Switzerland, May 27, 2015 -- (Healthcare Sales & Marketing Network) -- Helsinn Group, the Swiss Group focus... Biopharmaceuticals, RegulatoryHelsinn Group, ALOXI, palonosetron, CINV (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 27, 2015 Category: Pharmaceuticals Source Type: news

FDA OKs Aloxi for Chemo-Induced Nausea, Vomiting in ChildrenFDA OKs Aloxi for Chemo-Induced Nausea, Vomiting in Children
The FDA has approved palonosetron HCL (Aloxi, Eisai Inc and Hensinn Group) injection for the prevention of chemotherapy-induced nausea and vomiting in children aged 1 month to less than 17 years. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 2, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Eisai's antiemetic agent Aloxi gets FDA approval to treat children
Japan-based Eisai has received approval from the US Food and Drug Administration (FDA) for antiemetic agent Aloxi (palonosetron HCI) as an additional indication for preventing acute nausea and vomiting associated with initial and repeat courses of em… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 1, 2014 Category: Pharmaceuticals Source Type: news

Aloxi (Palonosetron hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 18, 2014 Category: Drugs & Pharmacology Source Type: news

New Treatment Options Featured in NCCN Antiemesis Guidelines
JENKINTOWN, PA, April 7, 2004 – On March 11, 2004, the National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announced a major update of the NCCN Antiemesis Clinical Practice Guidelines. The NCCN Antiemesis panel recently updated its guidelines for preventing chemotherapy-induced nausea and vomiting to add the 5-HT3 receptor antagonist palonosetron (Aloxi, MGI Pharma Inc.) to multiagent antiemetic regimens for use with highly and moder... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - April 7, 2004 Category: Cancer & Oncology Source Type: news